Evidence map›Paper›PMID 39976686›Full record

ArticleAnalytical and bioanalytical chemistry2025

A sensitive LC-MS/MS method for the quantification of serum epoxyeicosatrienoic and dihydroxyeicosatrienoic acids in the identification of diabetic kidney disease.

Yi Liu, Anxian Huang, Yongwei Jiang, Xiaomu Kong, Meimei Zhao, Peng Gao, Ming Yang, Ziqing Kong, Wei Jia, Yongtong Cao and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi Liu *Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.
Anxian Huang *Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Calibra Scientific, Inc., Hangzhou, China.
Yongwei JiangDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.
Xiaomu KongDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.
Meimei ZhaoDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.
Peng GaoDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.
Ming YangDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.
Ziqing KongKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Calibra Scientific, Inc., Hangzhou, China.
Wei JiaKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Calibra Scientific, Inc., Hangzhou, China. jiawei6@zju.edu.cn.
Yongtong CaoDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China. caoyongtong100@sina.com.
Liang MaDepartment of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China. liangma321@163.com.

Funding

Elite Medical Professionals Project of China-Japan Friendship Hospital ZRJY2024-BJ02National Natural Science Foundation of China 82074221
6 · The paper itself

Abstract

Epoxyeicosatrienoic acids (EETs) are vasoactive eicosanoids with vasodilatory, anti-inflammatory, and nephroprotective properties, and metabolized to low-bioactive dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase. Evidence from animal studies suggests that EETs may be potential biomarkers for diabetic kidney disease (DKD). The aim of this study was to establish a simple, sensitive and accurate LC-MS/MS method for quantifying EETs and DHETs in human serum. Samples were prepared by solid phase extraction and quantified using a "one-to-one" isotope internal standard approach. The assay required a 9-min run time per sample. EETs and DHETs demonstrated good linearity over the investigated concentration range (r

Indexed as

8,11,14-Eicosatrienoic AcidDiabetic NephropathiesTandem Mass SpectrometryBiomarkersChromatography, LiquidEicosanoidsFemaleHumansLimit of DetectionLiquid Chromatography-Mass SpectrometryMaleMiddle AgedReproducibility of ResultsSolid Phase Extraction8,11,14-Eicosatrienoic AcidBiomarkersEicosanoidsBiomarkersDiabetic kidney diseaseDihydroxyeicosatrienoic acidsEpoxyeicosatrienoic acidsLC-MS/MS

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.